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A B S T R A C T   
A shared characteristic of many tumors is the lack of response to anticancer drugs. Multiple mechanisms of 
pharmacoresistance (MPRs) are involved in permitting cancer cells to overcome the effect of these agents. 
Pharmacoresistance can be primary (intrinsic) or secondary (acquired), i.e., triggered or enhanced in response to 
the treatment. Moreover, MPRs usually result in the lack of sensitivity to several agents, which accounts for 
diverse multidrug-resistant (MDR) phenotypes. MPRs are based on the dynamic expression of more than one 
hundred genes, constituting the so-called resistome. Alternative splicing (AS) during pre-mRNA maturation re-
sults in changes affecting proteins involved in the resistome. The resulting splicing variants (SVs) reduce the 
efficacy of anticancer drugs by lowering the intracellular levels of active agents, altering molecular targets, 
enhancing both DNA repair ability and defensive mechanism of tumors, inducing changes in the balance between 
pro-survival and pro-apoptosis signals, modifying interactions with the tumor microenvironment, and favoring 
malignant phenotypic transitions. Reasons accounting for cancer-associated aberrant splicing include mutations 
that create or disrupt splicing sites or splicing enhancers or silencers, abnormal expression of splicing factors, and 
impaired signaling pathways affecting the activity of the splicing machinery. Here we have reviewed the impact 
of AS on MPR in cancer cells.   
1. Introduction 
In humans, at least 20,000 genes encode a highly interindividual 
diverse proteome comprising between 250,000 and 1,000,000 proteins 
[1]. The comparison of these numbers suggests that the synthesis of such 
a great variety of proteins present in our body primarily requires the 
diverse expression of our genes, whose activity is regulated at the 
transcriptional, post-transcriptional, and translational levels [2]. One of 
the processes responsible for this proteome complexity is the variability 
in editing immature mRNA (pre-mRNA) by splicing. This process is 
regulated by a high number of “splicing factors”. These are proteins 
involved in the cut of introns from strings of pre-RNA and the 
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subsequent paste of adjacent exons. Splicing factors are either regulatory 
proteins or direct components of a multi-megadalton ribonucleoprotein 
complex named the spliceosome, which acts at the same time as tran-
scription occurs, by removal of introns and re-connection of exons as an 
integrated element of the gene regulatory network [3]. In “constitutive 
splicing”, the process occurs at canonical sites of pre-mRNA, whereas in 
“alternative splicing” (AS), the cut-and-paste mechanism involves 
different splicing sites, which result in diverse forms of partial or com-
plete removal or retention of introns and exons, respectively [4]. As 
splicing of a single pre-mRNA can produce more than one mature mRNA 
transcript called splicing variant (SV), multiple protein isoforms, which 
may be structurally and functionally dissimilar, could be generated by 
AS. Because more than 95% of human genes can undergo AS [4,5], this 
diversity substantially increases the coding capacity of our genome [6]. 
On the other hand, aberrant splicing has been associated with several 
diseases, including cancer. 
Despite the marked heterogeneity among types of cancer, among 
tumors of the same type, or even among tumors of the same patient, a 
shared characteristic of many tumors is their lack of response to phar-
macological treatment, which is accounted for by multiple mechanisms 
of pharmacoresistance (MPRs). This characteristic of cancer cells can be 
primary (intrinsic pharmacoresistance) or secondary (acquired phar-
macoresistance) triggered or enhanced in response to the treatment, 
which altogether can lead to diverse multidrug-resistant (MDR) phe-
notypes. MPRs are based on the dynamically changing expression of 
more than one hundred genes, constituting the so-called resistome, 
which is markedly affected by AS [7]. MPRs have been classified into 
seven groups (Fig. 1) [8,9] depending on whether they hinder the effi-
cacy of anticancer drugs by: i) lowering the intracellular amount of total 
drug either by reducing drug uptake (MPR-1a) or enhancing drug export 
(MPR-1b); ii) changing the proportion (MPR-2) of active agents inside 
cancer cells; iii) altering molecular targets (MPR-3); iv) enhancing both 
DNA repair ability and defensive mechanism of tumors (MPR-4); v) 
inducing changes in the balance between pro-survival and pro-apoptosis 
signals (MPR-5); vi) modifying interactions with the tumor microenvi-
ronment (MPR-6); and vii) favoring malignant phenotypic transitions 
(MPR-7). In the present review, we have analyzed the role of AS in 
determining the resistome of cancer cells in general. Nevertheless, it 
should be kept in mind that a precise understanding of the lack of 
response to pharmacotherapy in any specific type of cancer during 
clinical practice requires taking into account additional characteristics 
of the individual cancer phenotype, not considered here, that markedly 
affect the overall impact of MPRs on each patient outcomes. 
2. The exon-recognition process 
There are four types of introns. Those included in Groups I and II are 
removed through an autocatalytic reaction. Group I introns are found in 
some ribosomal RNA (rRNA), whereas Group II introns are found in 
rRNA, tRNA, and mRNA of fungal organelles, plants, and protists 
[10–13]. Group IV introns are found in tRNA genes. They need endo-
nucleases and ligases to be processed [14]. Introns considered in the 
present review belong to Group III. These introns are removed by the 
spliceosome after the definition of their limits in pre-mRNA, which is 
based on their sequence and structure. In the exon-recognition process, a 
critical role is played by specific sequences: two located at the 
intron–exon junction, i.e., the 5′ donor site (5′SS) and the 3′ acceptor site 
(3′SS), and an internal sequence, the branch point site (BPS), located 
18–40 nt from the 3′ ending edge of the intron. Group III introns can be 
classified into two subtypes, U2 and U12, depending on the class of 
spliceosome involved in their excision. Splicing of U2 introns, the most 
common type of introns in mammalian cells (more than 99% in humans) 
is performed by the so-called “major spliceosome” while the “minor 
spliceosome” is responsible for the removal of U12 introns [15–17]. 
The spliceosome is a multi-protein complex whose composition and 
conformation dynamically changes as exon-definition progresses from 
Complex E to subsequent Complexes A, B, and C (Fig. 2), before the cut- 
and-paste reactions start. The formation of the early E’ complex triggers 
the beginning of the exon-recognition process. The nucleotide sequences 
of the pre-mRNA identified by the major spliceosome are GU at 5′SS and 
AG at 3′SS [18], whereas in the minor spliceosome, the equivalent se-
quences are AU and AC, respectively [17,19,20]. Major spliceosome 
assembly begins with a base pairing of GU at 5′SS with U1 small nuclear 
ribonucleoprotein (snRNP) (Fig. 2A). U1 snRNP belongs to a group of 
snRNPs consisting of: i) one of the five types (U1, U2, U4, U5, and U6) of 
small nuclear RNA (snRNA), which are RNA sequences of usually about 
150 nucleotides in length; and ii) seven Sm proteins to generate the 
central region of the snRNP particle (Table 1). Sm proteins are necessary 
for the biogenesis, transport, and function of snRNP particles [21] and 
are crucial for their metabolic stability. In the case of U1 snRNP, the 
complex also includes three specific proteins, namely, U1 snRNP 70 kDa, 
U1A snRNP, and U1C snRNP [20] (Table 1). Moreover, during the exon- 
definition process, the splicing factor 1 (Sf1) binds to the BPS in an ATP- 
independent manner (Fig. 2A). The early E complex is then formed by 
recruitment of the U2 heterodimer (U2af), consisting of two subunits of 
35 kDa (U2af1) and 65 kDa (U2af2), which bind to the 3′SS and the 
polypyrimidine tract (PPT), respectively [22] (Fig. 2B, Table 1). 
The next step is the formation of the A complex, in which snRNP-U2 
displaces Sf1, in an ATP-dependent manner. This process is catalyzed by 
the RNA helicases DDX46 (PRP5 in yeasts) and DDX39B (SUB2 in 
yeasts). DDX46/PRP5 assists in the binding of U2-subunit with U1- 
subunit [23], whereas DDX39B/SUB2 is required to stabilize the inter-
action between U2 subunit and pre-mRNA BPS [24] (Fig. 2C, Table 1). 
To generate the next structure, U4/U6-U5 tri-snRNP recruitment to the 
donor site occurs, forming the pre-catalytic B complex (B1), U5 binds to 
the 5′ end of the exon, and U6 binds to U2 (Fig. 2D). 
In the next step, U1 and U4 snRNPs are released, which results in the 
activation of the spliceosome (activated B complex or B2 complex) [25]. 
The triggered catalytic activity of pre-mRNA processing factors included 
in the B2 complex [26], mediates the first reaction of splicing, producing 
an intermediate with lariat structure containing the 3′ intron loop [27] 
(Fig. 2E). Next, the spliceosome undergoes a conformational change, 
becoming the C complex, in which a different catalytically active ap-
pears [28,29]. Thus, U6 and U2 catalyze the second step, which by 
Fig. 1. Scheme of the seven groups of mechanisms of pharmacoresistance 
(MPR) and the genes of the resistome that are affected by alternative splicing in 
cancer cells. 
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transesterification reactions, will join the exons after removing the 
intron with the loop structure, which is rapidly degraded by the cell 
[30–32]. In the minor spliceosome, ribonucleoproteins involved in this 
process are U11, U12, U4ATAC, U5, and U6ATAC [18]. 
A critical point in the splicing process is that the spliceosome must 
identify specific regions at the intron–exon borders to perform intron 
excision and exon binding accurately, despite the complexity accounted 
by the fact that exons constitute less than 1.1% of the human genome 
versus the 25% of introns. Differences in guanine and cytosine content 
between exons and introns, together with the existence of the afore-
mentioned tag sequences (5′SS, 3′SS, BPS and PPT), make it possible to 
identify the exons for their processing by the spliceosome. Besides, there 
are cis-regulatory sequences named according to their position and 
function as exonic splicing enhancers (ESE), exonic splicing silencers 
(ESS), intronic splicing enhancers (ISE), and intronic splicing silencers 
(ISS) (Fig. 3). The definition of sequences to be removed depends partly 
on the interaction of pre-mRNA with many regulatory proteins that 
interact with these sites [18,20,33,34]. Thus, SR proteins (Table 1), 
characterized by a domain rich in arginine and serine di-peptides, favor 
short splicing due to their ability to bind to ESE and ISE [35]. SR proteins 
are concentrated in interchromatin granules or speckles [36], where 
splicing occurs [37] (Fig. 3). In contrast, heterogeneous nuclear ribo-
nucleoproteins (hnRNPs) (Table 1) favor long splicing by inhibiting 
short splicing through interaction with both ESS and ISS [38] (Fig. 3). 
Besides, several kinases and phosphatases (Table 1) are involved in 
regulating of the spliceosome by changing the activity of SR proteins 
through phosphorylation and dephosphorylation, respectively [39]. The 
degree of complexity due to AS of pre-mRNA in target genes is increased 
because components of the splicing machinery and regulatory proteins 
involved in exon-recognition can themselves undergo AS, generating 
different isoforms (Table 1), which can modify the overall result of the 
splicing process. 
3. Genetic events affecting the spliceosome and regulatory 
proteins in cancer 
Since splicing dysregulation is a hallmark of cancer, it is not sur-
prising that there are more than 15,000 tumor-associated SVs described 
in a wide variety of malignancies [40,41]. For instance, in a cell model of 
breast cancer, 1723 splicing alterations in target genes and changes in 
the expression of 41 splicing factors have been reported [42]. In most 
cases, these variants result from aberrant splicing, which produces 
proteins that alter, often favoring, critical aspects of cancer cell biology 
[43–45]. Besides generating abnormal proteins, AS can produce aber-
rant forms of mRNAs containing “poison exons”, which lead to enhanced 
sequestration and degradation of specific “healthy” mRNAs in the nu-
cleus, and hence alter cancer cells phenotype [46]. 
The mechanisms accounting for alterations in splicing observed in 
cancer cells include: i) abnormal expression of spliceosome components 
and regulatory proteins, which may affect their own splicing and hence 
the functional balance among their isoforms (Table 1) [47]; ii) muta-
tions in these proteins; iii) mutations that create or disrupt splicing 
donor or acceptor sites or splicing enhancers or silencers in target pre- 
mRNAs [48,49]; and iv) changes in cell signaling pathways affecting 
the activity of the splicing machinery [48,50] (Table 1). Moreover, non- 
coding RNAs (ncRNAs), which include microRNAs (miRNAs), long non- 
coding RNAs (lncRNAs), circular RNAs (circRNAs), and small nuclear 
RNAs (snRNAs), have a marked impact on AS in cancer [51], which is 
yet not fully understood. Finally, nonsense-mediated mRNA decay 
(NMD) is a key mechanism for elimination of aberrant splicing isoforms. 
Accordingly, when NMD is impaired, aberrant transcripts persist in the 
tumor. UPF1 is the most commonly altered NMD factor in cancer. Be-
sides downregulation, UPF1 often harbors splice site mutations itself 
[52]. 
Essential components of the U2 complex are SF3 proteins (Table 1). 
One of them is SF3B1, which has been identified as a driver protein in 
many cancers [53]. Regarding core proteins involved in E complex 
formation, the expression of SNRPB and SNRPD1 is higher in several 
tumors as compared with adjacent tissue. This is the case of hepatocel-
lular carcinoma (HCC), in which up-regulation of both splicing factors 
has been correlated with shorter overall survival (OS) [54]. The 
expression of SNRPB is also increased in gliomas [55,56] and in non- 
small cell lung cancer (NSCLC) [57]. In these cancers, the tumorigenic 
capacity of SNRPB seems to be mediated, in part, by an SV of RAB26 that 
includes intron 7, whose generation is promoted by up-regulated SNRPB 
[57]. Altered expression of several hnRNPs has been found to be asso-
ciated with cancer development in several organs. Thus, hnRNPE1 
(PCBP1) acts as a tumor suppressor and is down-regulated in many 
cancers. In contrast, hnRNPE2 (PCBP2) and hnRNPK are considered 
oncogenes and promote tumorigenesis [58–61]. Among SR proteins, 
SRSF1, SRSF3, SRSF5, and SRSF9, which are considered indirect onco-
genes, are up-regulated in several tumors [62–66]. Furthermore, as 
mentioned above, pre-mRNA of splicing factors (e.g., SRSF3) can un-
dergo AS resulting in altered proteins with impact on the overall func-
tion of the spliceosome leading to changes in resistome profile and 
Fig. 2. Simplified scheme of exon-recognition process during splicing. (A) The 
splicing factor 1 (Sf1) binds to the BPS. (B) The early E complex is formed by 
recruitment of the U2 heterodimer U2af1/U2af2, which bind to the 3′SS and the 
polypyrimidine tract (PPT). (C) To generate the A complex, snRNP-U2 displaces 
Sf1, which is catalyzed by the RNA helicases DDX46 and DDX39B. (D) The 
recruitment of U4/U6-U5 tri-snRNP to the donor site occurs, forms the pre- 
catalytic B1 complex. (E) U1 and U4 snRNPs are released, resulting in the 
activation of the spliceosome (B2 complex), which is followed by the first re-
action of splicing, producing an intermediate with lariat structure containing 
the 3′ intron loop, forming the C complex. 




Components of the splicing machinery and regulatory proteins involved in exon-recognition, existence of splicing variants (SV), cancer-associated changes and known impact on mechanisms of pharmacoresistance (MPR).  
Role Gene (Protein) SV Change MPR Ref. 
They form part of U1 snRNP. 
Essential in the recognition of 5′SS and subsequent spliceosome assembly. 
SNRNP70 (U1 snRNP 70kD) 2 nd   
SNRPA (U1A snRNP) 1 nd   
SNRPC (U1C snRNP) 1 nd   
Sm proteins constitute the central region of the snRNP particles U1, U2, U4/U6, and U5, which are involved in Complex E, A, B, and C. SNRPB/B1 (sm-B/B1) 2 + [55,57] 
SNRPD1 (sm-D1) 2 + [54] 
SNRPE (sm-E) 4 nd   
SNRPF (sm-F) 2 nd   
SNRPG (sm-G) 6 nd   
SNRPN (sm-N) 3 nd   
Interaction with U1 and U2 snRNPs. 
Recognition of 3′SS and PPT. 
Initial assembly of Complex E. 
SF1 (Sf1) 11 -/*  [54] 
U2AF1 (U2af1) 3 -/*  [148] 
U2AF2 (U2af2) 2 *  [149] 
Part of U2 snRNP. 
Critical role in spliceosome assembly. 
SF3A1 (SF3A1) 1 nd   
SF3A2 (SF3A2) 1 nd   
SF3A3 (SF3A3) 2 nd   
SF3B1 (SF3B1) 3 +/* 5, 7 [102,143,150–154]. 
SF3B2 (SF3B2) 3 nd   
SF3B3 (SF3B3) 1 + [130,155] 
SF3B4 (SF3B4) 1 nd   
Helicases interacting with U2 snRNP. 
They are involved in Complex A, B and C 
DDX46 (DDX46) 2 nd   
DDX39B (DDX39B) 1 nd   
SR proteins can modify the selection of splicing sites. 
They bind to intronic (ISE) and exonic (ESE) splicing enhancer sites stimulating short splicing. 
They contain an RNA recognition motif (RRM) for binding RNA and an RS domain rich in serine and arginine residues for binding other proteins. 
SR proteins are also involved in mRNA export from the nucleus and in translation. 
SRSF1 (SFE2/ASF) 2 +/- 5, 7 [62,66,102,105,143] 
SRSF2 (SC35) 1 -/*  [156,157] 
SRSF3 (SRp20) 1 +/- 1 [62–67] 
SRSF4 (SRp75) 1 –   
SRSF5 (SRp40) 3 +/-  [62–66] 
SRSF6 (SRp55) 1 nd   
SRSF7 (9G8) 3 –  [54] 
SRSF8 (SRp46) 1 –  [54] 
SRSF9 (SRp30c) 1 + [62–66] 
SRSF10 (TASR) 1 + [65] 
SRSF11 (NET2) 9 nd   
SRSF12 (SREK1) 2 nd   
SRRM1 (SRm160) 26 –  [54] 
RBM5 (LUCA15) 7 nd   
hnRNPs can modify the selection of splicing sites. 
They bind to intronic (ISS) and exonic (ESS) splicing silencer sites, inhibiting short splicing. 
Participates in the transport of mRNA with poly(A) from the nucleus to the cytoplasm. 
HNRPA1 (hnRNPA1) 2 nd 3, 5 [94,95,122] 
HNRNPAB (hnRNP A/B) 2 + 7 [140] 
HNRNPA2B1 (hnRNP B1) 3 nd   
HNRNPD (hnRNP D) 4 +/-  [54,158] 
PCBP1 or HNRNPE1 (PCBP1) 1 – 5 [58,59,121] 
PCBP2 or HNRNPE2 (PCBP2) 7 + [60,61] 
HNRNPF (hnRNP F) 1 nd   
HNRNPH1 (hnRNP H1) 4 + [145] 
HNRNPH2 (hnRNP H2) 2 nd 2 [85] 
HNRNPI (PTBP1) 3 + 1 [81] 
HNRNPK (hnRNP K) 4 + [159–161] 
HNRNPL (hnRNP L) 2 +/-  [162,163] 
HNRNPM (hnRNP M) 3 + 7 [133] 
CDC-like kinases (CLKs) are nuclear kinases involved in the phosphorylation of SR proteins in the nucleus. CLK1 (CLK1) 2 –  [54] 
CLK2 (CLK2) 4 nd   
CLK3 (CLK3) 2 nd   
CLK4 (CLK4) 1 nd   
SR protein kinases (SRPKs) are cytoplasmic kinases that phosphorylate SR proteins. 
They specifically phosphorylate their substrates in serine residues located in regions rich in arginine/serine dipeptides. 
SRPK1 (SRPK1) 1 nd 5 [120] 
SRPK2 (SRPK2) 9 nd   
Serine/threonine specific phosphatases involved in the regulation of SR proteins by removing phosphate groups. PPP1CA (PP1A) 3 nd   
PPP2CA (PP2A) 2 nd   
Reported changes in cancer: +, up-regulation; -, down-regulation; *, mutations; nd, not described. 
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subsequent enhancement of pharmacoresistance. Thus, SRSF3 pre- 
mRNA undergoes AS affecting exon 4. The short SV lacking exon 4 en-
codes the full-length SRSF3 protein. In contrast, the long isoform, which 
includes exon 4 (SRSF3ex4), encodes a truncated SRSF3 protein due to 
an earlier termination codon, leading to enhanced resistance to pacli-
taxel in breast cancer and oral squamous cell carcinoma (OSCC) cells 
[67]. 
4. Role of AS in MPR-1. Changes in drug transporters 
Mechanisms affecting the response of cancer cells to pharmaco-
therapy can be modified by the expression of SVs (Fig. 1, Table 2). This is 
the case of MPR-1, which accounts for changes in the uptake and efflux 
of antitumor drugs in cancer cells. The SLC superfamily of proteins 
currently includes 458 transporters classified into 65 families that 
transport a wide variety of substances across cell membranes; some of 
them play a crucial role in drug uptake [68]. An example is the organic 
cation transporter 1 (OCT1, SLC22A1), which is expressed at the baso-
lateral membrane of hepatocytes and other healthy cells. This trans-
porter plays an important role in the uptake of some antitumor drugs 
such as imatinib and sorafenib by cancer cells [69]. Several OCT1 SVs 
have been identified. Most of them are generated by exon skipping, 
which results in shorter OCT1 isoforms without transport activity. Thus, 
non-functional SVs, mainly due to exon 10, exon 9, and exon 9 + 10 
skipping, are frequently expressed in HCC and cholangiocarcinoma 
(CCA) [70]. Besides, some OCT1 SVs have been associated with the lack 
of response of chronic myeloid leukemia (CML) to imatinib [71] and 
HCC to sorafenib [72,73]. 
The equilibrative nucleoside transporter 1 (ENT1, SLC29A1) is 
involved in the uptake of some nucleoside-related drugs. An intronic 
mutation in ENT1 that disrupts the splicing of exon 13 causes impaired 
cytarabine uptake in leukemia cell lines [74]. 
Organic anion transporter polypeptide 1B3 (OATP1B3, SLCO1B3) is 
involved in the uptake of anticancer drugs, such as paclitaxel, docetaxel, 
methotrexate, SN-38, platinum-based drugs, and several tyrosine kinase 
inhibitors (TKIs). Under physiological conditions, the so-called liver- 
type isoform (Lt-OATP1B3) is highly expressed at the basolateral plasma 
membrane of hepatocytes. However, in several primary solid tumors 
generated in the colon, lung, pancreatic, ovarian, prostate, bladder, and 
breast, the cancer-type variant (Ct-OATP1B3) has been identified 
[75–77]. Compared with Lt-OATP1B3, the transcription start site of Ct- 
OATP1B3 mRNA is delayed to the second intron of this gene, and hence, 
the predicted Ct-OATP1B3 ORF lacks part of the N-terminal coding re-
gion of Lt-OATP1B3 [78,79]. Although it is still unclear, there is evi-
dence supporting that Ct-OATP1B3 has minimal or negligible transport 
activity. Nevertheless, Ct-OATP1B3 seems to confer proliferation 
advantage and chemotherapy resistance to cancer cells [79,80]. 
Multidrug resistance-associated protein 1 (MRP1, ABCC1) is one of 
the ATP-binding cassette (ABC) pumps able to export anticancer drugs 
from cancer cells, conferring pharmacoresistance. More than twenty SVs 
of MRP1 have been described in cancer (e.g., ovarian cancer), with a 
higher expression in tumor than in adjacent non-tumor tissue. These SVs 
are generated by partial exon skipping and intron inclusion, mainly 
between exons 10 and 19. Interestingly, the paired analysis in the same 
tumor samples, revealed enhanced expression of splicing factors poly-
pyrimidine tract binding protein 1 (PTBP1, HNRNPI) and SRp20 (SRSF3) 
(Table 1). The in vitro study of the functional repercussions of these 
MPR1 SVs showed that MRP1–2 k (exons 12–26 skipped and 99 nucle-
otides of exon 27 skipped), MRP1-d5d30 (exon 5 and 30 skipped), and 
MRP1-d17d18 (exon 17 and 18 skipped) still conferred doxorubicin 
resistance. However, they were not as potent as the full-length wild-type 
MRP1 [81]. 
5. Role of AS in MPR-2. Changes affecting pro-drug activation 
and drug inactivation 
Mechanisms altering the proportion of active versus inactive drugs 
inside cancer cells are classified as MPR-2 (Fig. 1, Table 2). Carbox-
ylesterases (CES) catalyze the hydrolysis of a wide variety of com-
pounds. CES2 is involved in the intracellular activation of irinotecan 
into its active metabolite SN-38. Six SVs can be formed by combining 
different ATG start sites and two splicing events. Alternate 5′-splicing in 
exon 10 removes 48 nucleotides from CES2 pre-mRNA generating the 
CES2Δ458-473 variant, which lacks 16 amino acids in the proximity of 
the active site resulting in impaired esterase activity. Consequently, the 
conversion of irinotecan into SN-38 is hampered. Nevertheless, since 
CES2Δ458-473 constitutes only a small proportion (6%) of total CES2, 
at least in colon cancer, it is unclear that this AS could play an essential 
role in determining irinotecan pharmacokinetics and therapeutic 
outcome of these patients [82]. 
Deoxycytidine kinase (DCK) is an intracellular enzyme required to 
activate cytarabine. Several SVs have been identified in cytarabine- 
resistant acute myeloid leukemia (AML), which are absent from sensi-
tive leukemia cells and healthy leukocytes [83,84]. Besides, SVs lacking 
exon 2 and exon 3, due to intronic mutations, were found in cytarabine- 
resistant leukemia cells [74]. 
Thymidine phosphorylase (TP, TYMP) is a crucial enzyme in the first 
step of metabolic biotransformation of 5-fluorouracil (5-FU) into the 
active metabolite fluorodeoxyuridine monophosphate. Leukemia cells 
with enhanced 5-FU resistance present partly un-spliced TYMP pre- 
mRNA, which results in introns 1–6 still included in the major tran-
script. The consequence is the presence of a premature stop codon in this 
SV which is translated into a dysfunctional enzyme unable to activate 5- 
FU. The generation of this SV has been associated with an enhanced 
nuclear abundance of hnRNPH2, which acts as an inhibitor of exon 
recognition [85]. 
Dihydropyrimidine dehydrogenase (DPD) is the main enzyme ac-
counting for capecitabine catabolism. DPD overexpression induces a 
lack of sensitivity to capecitabine. However, on the other hand, reduced 
DPD activity may result in enhanced drug toxicity in patients receiving 
capecitabine. The rs3918290 SNP located in intron 14 is associated with 
an alteration of the splicing donor site, which results in the generation of 
the variant DPYD*2A by exon 14 skipping. Besides, the rs67376798 SNP 
located in exon 22 probably generates a broken ESE site together with a 
new ESS site. These changes alter exon recognition, which produces 
aberrant transcripts that are translated into proteins with deficient 
enzymatic activity. These variants have been significantly associated 
with increased capecitabine-induced toxicity in patients treated with 
this drug [86]. 
The intracellular retention of folates and antifolates drugs, such as 
methotrexate depends on conjugation through their gamma-carboxyl 
residue with multiple glutamate moieties, which is catalyzed by the 
enzyme folyl-poly-gamma-glutamate synthetase (FPGS), whose activity 
is reduced in acute lymphoblastic leukemia cells with decreased sensi-
tivity to these drugs. This can be due in part to aberrant splicing, which 
results in a dysfunctional SVs generated by exon 12 skipping and intron 
8 partial retention [87–89]. 
6. Role of AS in MPR-3. Changes affecting drug targets 
The group of MPR-3 includes changes affecting drug targets (Fig. 1, 
Table 2). Imatinib is a TKI targeting the oncogenic BCR-ABL fusion 
protein, used to treat some malignancies, such as chronic myeloid leu-
kemia (CML). In this cancer, point mutations affecting the kinase 
domain of the BCR-ABL gene often result in imatinib resistance. Besides, 
SVs, such as BCR-ABL35INS, which leads to premature termination of 
the protein and results in an inactive kinase domain, have been associ-
ated with inadequate response to imatinib treatment [83]. 
Vemurafenib inhibits cell growth acting on the RAS-MAPK pathway. 
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This antitumor drug is used in melanoma treatment because it inhibits 
the BRAF p.V600E, which is the most frequent isoform in this skin 
cancer [90]. However, a shorter protein (C3 variant) encoded by a SV of 
BRAF p.V600E, generated by exon 4–8 skipping, is found in melanomas 
characterized by vemurafenib resistance [91,92]. The appearance of this 
SV leads to constitutive dimerization of BRAF p.V600E in a RAS- 
independent manner. Interestingly, using both in vitro and in vivo 
models, it has been shown the spliceostatin A (or its analog meayamycin 
B), a compound that targets SF3B1, can reverse the resistance to 
vemurafenib in melanomas harboring BRAF p.V600E SVs [93]. 
The androgen receptor (AR) is a critical therapeutic target for 
treating some tumors. The SV AR-V7, which has been detected in 
hormone-refractory prostate cancer, presents exons 4–7 skipping, which 
generates a functional protein lacking the ligand-binding domain. Thus, 
tumors expressing AR-V7 exhibit resistance to anti-AR drugs, such as 
enzalutamide and abiraterone. In vitro studies have demonstrated that 
hnRNPA1 inhibition by quercetin can prevent the generation of AR-V7 
and re-sensitize prostate cancer cells to enzalutamide [94,95]. 
Tamoxifen is used in the treatment of estrogen receptor (ER)-positive 
breast cancer. However, in some tumors, SV ERα36 is expressed. In this 
SV, the transcription is initiated from different promoters located in the 
first intron. Hence, ERα36 lacks the transcriptional activation domains 
and shows a worse tamoxifen response than tumors expressing the full- 
length wild-type ERα [96]. 
Acquired resistance to TOP2α inhibitors, such as mitoxantrone, 
etoposide, teniposide, daunorubicin, and doxorubicin, is frequently 
associated with a decreased level of TOP2α expression. Similarly, several 
truncated isoforms of TOP2α originated by AS resulting in reduced drug 
activity against TOP2α [97]. 
Ten-eleven translocation-2 (TET2) modulates DNA hydrox-
ymethylation by converting 5-methylcytosine into 5-hydroxymethylcy-
tosine to promote DNA demethylation. Skipping of exon 2 in TET2 
pre-mRNA by AS results in cytarabine resistance of AML cells [7,98]. 
7. Role of AS in MPR-4. Changes affecting DNA repair 
Some antitumor drugs, such as platinum-derived agents or inhibitors 
of poly(ADP-ribose) polymerase (PARP), induce double-stranded DNA 
breaks, which can be repaired by the homologous recombination (HR) 
DNA repair system. Enhanced tumor ability of DNA repair or protection 
have been classified as MPR-4 (Fig. 1, Table 2). BRCA1/2 proteins are 
essential for efficient HR-mediated DNA repair. Because tumors, such as 
breast or ovarian cancer, present a high frequency of loss-of-function 
mutations in BRCA1 and BRCA2 genes, these malignacies are poten-
tially sensitive to PARP inhibitors (PARPi) and platinum-based treat-
ment. However, in some cases, acquired resistance has been attributed 
to aberrant splicing of BRCA1 pre-mRNA that generates the BRCA1- 
Δ11q variant, in which most part of exon 11, containing inactivating 
mutations of this gene, is skipped. Consequently, the sensitivity to PARPi 
and platinum therapy are partly lost [99]. In vitro assays revealed that 
the sensitivity to PARPi was restored using an inhibitor of the U2 snRNP 
spliceosome machinery [99]. Aberrant splicing of BRCA2 has also been 
associated with acquired drug resistance. Thus, compared to the wild- 
type BCRA2 protein, the BRCA2ΔE5 + 7 SV, lacking exons 5 and 7, 
encodes an in-frame shorter protein due to the internal deletion of 55 
amino acids. Hence, the expression of this SV induces mitomycin C 
resistance in AML cells [100]. 
An essential element of the nucleotide excision repair (NER) mech-
anism is excision repair cross complementation group-1 (ERCC1), 
capable of repairing cisplatin-induced DNA damage. In ovarian cancer, 
treatment with cisplatin favors the appearance of a functional SV of 
ERCC1, which results in a longer transcript and provides increased 
resistance to cisplatin [101]. 
8. Role of AS in MPR-5. Changes affecting apoptosis/survival 
balance 
As most anticancer agents aim to activate apoptosis in the tumor 
selectively, the imbalance between pro-apoptotic and pro-survival fac-
tors commonly occurring in cancer cells hamper the response to phar-
macotherapy, through processes classified as MPR-5 (Fig. 1, Table 2). 
Epithelial cell transforming 2 (ECT2) is a guanine nucleotide exchange 
factor involved in cell cycle regulation. ECT2-exon 5 inclusion levels are 
associated with poor prognosis in breast cancer after chemotherapy. 
This SV is favored by splicing factors ZRANB2 and SYF2 up-regulation, 
which leads to acquired resistance to doxorubicin [42]. 
Owing to aberrant splicing, the generation of SVs of members of the 
BCL-2 family promotes anticancer drug resistance. MCL-1, BCL-X, and 
BID have SVs coding for isoforms with opposite pro-apoptotic and anti- 
apoptotic activities. MCL-1 splicing is partially regulated by SF3B1, 
which explains why, in NSCLC and cervical carcinoma, SF3B1 inhibition 
reverses the predominance of SVs (differing in exon 2) from the anti- 
apoptotic MCL-1L (long) to pro-apoptotic MCL-1S (short) [102,103]. 
BCL-X can also undergo AS to produce either the long anti-apoptotic 
Fig. 3. Role of major regulatory proteins (SRs and hnRNPs) in exon definition. BPS, branch point site; ESE, exonic splicing enhancer; ESS, exonic splicing silencer; 
ISE, intronic splicing enhancer; ISS, intronic splicing silencer; PPT, polypyrimidine tract. 




Splicing variants in genes associated with mechanisms of pharmacoresistance.  
MPR Gene (Protein) Splicing Event Impact Cancer Ref. 
1 SLC22A1 (hOCT1) TGGTAAGT insertion at exon 7 (rs113569197) No functional transporter 
Worse imatinib response 
CML [71] 
SLC29A1 (ENT1) Exon 13 skipping Absence of plasma membrane expression of ENT1. Impaired cytarabine uptake in vitro LK [74] 
SLCO1B3 
(OATP1B3) 
Ct-OATP1B3 (transcription start site in intron 2) Minimal or negligible transport activity. Absence of plasma membrane location. Lack of transport ability so 
possible link with drug resistance 
CAC, PDAC [79,80] 
ABCC1 (MRP1) MRP1–2 k; MRP1-d5d30; MRP1-d17d18 (all resulting in exon 
skipping) 
Maintained drug transport activity. Doxorubicine resistance in vitro, although less potent than the full- 
length MRP1 
OC [81] 
2 CES2 (CES2) CES2Δ458 – 473 Impaired esterase activity. Impaired conversion of irinotecan into SN-38 in vitro CAC [82] 
DCK (DCK) Exon (2–6) skipping Inactive proteins. Linked with cytarabine resistance in AML cells and patients AML [74,83,84] 
TYMP (TP) Introns (1– 6) retention Lack of protein. 5-FU resistance in vitro LK [85] 
DPYD (DPD) Intronic SNPs and aberrant splicing Low functionality of the enzyme. Increase toxicity in breast cancer patients treated with capecitabine BC [86] 
FPGS (FPGS) Exon 12 skipping and intron 8 partial retention Impaired polyglutamylation leading to decreased intracellular drug retention 
Lower response to methotrexate, dexamethasone, mitoxanthrone, and prednisolone 
ALL [9,87–89] 
3 BCR-ABL (BCR- 
ABL) 
BCR-ABL35INS (retention of 35 nt of intron 8) Protein with an inactive kinase domain. Poor response to imatinib treatment CML [164] 
BRAF (BRAF) BRAF C3 variant (exon 4–8 skipping) Constitutive dimerization of BRAF. Resistance to vemurafenib in vitro and in vivo models. Vemurafenib 
resistance in melanoma patients 
ML [91–93] 
AR (AR) AR-V7 (skipping of exons 4–7) Protein lacking the ligand binding domain. Patients expressing AR-V7 exhibit resistance to enzalutamide 
and abiraterone 
PC [93] 
ESR (ER) ERα36 (different promoter located in the first intron) Protein lacking transcriptional activation domains. Worse patient response to tamoxifen BC [96] 
TOP2A (TOP2α) Intron retention variants Truncated protein. 
Mitoxantrone resistance in vitro 
AML [97] 
SRSF3 (SRSF3) Exon inclusion (SRSF3ex4). Premature termination codon Paclitaxel resistance BC, OSCC [67] 
TET2 (TET2) Exon 2 skipping Impaired DNA demethylation. Cytarabine resistance AML [9,98] 
4 BRCA1 (BRCA1) BRCA1-Δ11q (exon 11 skipping) Bypass inactivating mutations of the protein. Partial resistance to PARPi and platinum therapy BC, OC [99] 
BRCA2 (BRCA2) BRCA2ΔE5+7 (exon 5 and 7 skipping) Protein lacking 55 amino acids 
Mitomycin C resistance in vitro 
AML [100] 
ERCC1 (ERCC1) Transcriptional start point located upstream of the normal one Larger ERCC1 transcript. Cisplatin resistance OC [101] 
5 ECT2 (ECT2) ZRANB2 and SYF2 up-regulation leading to ECT2 exon 5 
inclusion 
Doxorubicin resistance BC [42] 
BCL (BCL) BCL-XL (includes exon 2.1) Antiapoptotic variant 
Imatinib resistance in vitro and in vivo models 
CML, AML [104,165] 
BIM (BIM) BIM-γ Isoforms lacking the pro-apoptotic BCL2-homology domain 3 lead to imatinib resistance in vitro 
Patients with this variant respond worst to imatinib 
CML [106] 
TP53 (p53) Δ133p53 (different promoter vs full length TP53) Anti-p53 function. 5-FU resistance in vitro CCA [109] 
Δ133p53 Camptothecin resistance in vitro CAC [110] 
Δ40p53 (initiation of translation within intron 2, and deletion 
of 40 amino acids) 
Cisplatin resistance in vitro ML [111] 
Alternative splicing of exon 9b or 9 g Enhanced sensitivity to doxorubicin AML [112] 
BIRC5 (Survivin) Survivin-3B (intron 3 retention) Inhibits procaspase-6 
Cisplatin and 5-FU resistance in vitro 
BC, CAC, KC [113–115] 
Survivin-2B (includes additional exon 2.B) Blocks apoptosis induced by BAX Patients with this variant treated with cytarabine and mitoxantrone 
present worst OS 
AML [116] 
EIF4H (EIF4H) RBM10-dependent aberrant splicing Resistance to PI3K/AKT/mTOR inhibitors (e.g., AZD8055, BEZ235) LC [117] 
PIK3CD (PIK3CD) Exon 20 skipping Resistance to PI3K inhibitors, such as idelalisib and wortmannin PC [118] 
MNK2 (MNK2) Exclusion of part of the exon 13 Gemcitabine resistance PDAC [9,119] 
PKM (Pyruvate 
kinase) 
PKM2 (a mutually exclusive exon variant) Gemcitabine resistance in vitro PDAC [121] 
FGFR1 (FGFR1) Inclusion of intronic segments. Premature termination codon Enhanced pAKT activity 
Resistance to FGFR1 inhibitors, such as dovitinib 
SACC [123] 
6 RBM11 (RBM11) Enriched in EVs Altered splicing profiles (of MDM4 and Cyclin D1. Impaired apoptosis activation. GB [125] 




VEGFA (VEGFA) Alternative 3′ SS for exon 8 (VEGFA145b) Resistance to bevacizumab CAC [129] 
Release of EVs containing SF3B3 and hnRNPA3 Drug resistance by altered apoptosis activation AML [126] 
(continued on next page) 
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variant (BCL-XL) or the short pro-apoptotic one (BCL-XS). SF3B1 and 
SRSF1 partly orchestrate the generation of these SVs [102]. Thus, in 
cervical carcinoma, SRSF1 overexpression results in BCL-XL generation, 
whereas its down-regulation promotes BCL-XS formation [102]. In some 
cancers, the enhanced expression of BCL-XL often results in resistance to 
several drugs, such as imatinib [104]. The mechanism of action of this 
TKI involves stimulation of BIM (also named BCL2L11) transcription and 
post-translational activation of BIM protein, which induces apoptosis. 
AS of BIM may result in reduced sensitivity to imatinib and other TKIs. 
There is evidence indicating that SRSF1 promotes BIM AS [105]. Thus, 
the SV named BIM-γ, arising from exon 4-to-exon 3 switch due to an 
intronic deletion polymorphism, is correlated with resistance to imati-
nib and to other TKIs in CML and NSCLC cells [106,107]. 
AS of TP53 pre-mRNA accounts for the generation of 12 SVs [108]. 
These include three smaller variants, named P53β, Δ40p53, and 
Δ133p53, which are associated with drug resistance. Thus, Δ133p53, 
which exhibits anti-p53 function, has been related to 5-FU resistance in 
CCA cells [109] and can protect colorectal cancer cells from 
camptothecin-induced apoptosis [110]. Besides, Δ40p53 expressed in 
melanoma cells inhibits p53-dependent transcription of p21 and PUMA 
and contributes to cisplatin resistance [111]. In contrast, AS can also 
generate proteins associated with a better prognosis. For instance, 
truncated forms of p53 produced by AS of exon 9β or 9γ correlates with a 
more satisfactory response of AML to doxorubicin due to the increased 
promoter binding ability of those isoforms, which up-regulates tumor 
suppressor (e.g., p21) and of pro-apoptotic (e.g., BAX) genes [112]. 
A survivin (BIRC5) SV named survivin-3B is originated by intron 3 
retention. Survivin-3B binds and inhibits procaspase-6. Thus, this SV, 
which is highly expressed in cancer of several organs, such as breast, 
colon, and kidney, increases their resistance to cisplatin [113] and 5-FU 
[114,115]. Moreover, AS of BIRC5 pre-mRNA can generate survivin- 
ΔEx2, lacking exon 2, and survivin-2B, which contains an additional 
exon 2B. In AML patients treated with cytarabine and mitoxantrone 
regime, those with leukemia cells expressing higher levels of survivin-2B 
showed poorer OS than those with lower expression [116]. 
RBM10 encodes a nuclear protein that contains an RNA-binding 
motif through which RBM10 interacts with hnRNPs to regulate AS of 
its target genes, such as eukaryotic translation initiation factor 4H 
(EIF4H). Lung cancer patients with low RBM10 expression have reduced 
survival rates. RBM10-dependent aberrant splicing of EIF4H in cancer 
cells results in gain-of-function SVs leading to resistance to PI3K/AKT/ 
mTOR inhibitors (e.g., AZD8055, BEZ235) [117]. 
Several mutations in PI3K result in constitutive activation of the 
PI3K/AKT/mTOR signaling pathway, which is associated with cancer 
progression. Two PIK3CD mRNAs are expressed in prostate cancer, i.e., 
PIK3CD-L (long variant) and PIK3CD-S (lacking exon 20). The latter is 
translated into a PI3Kδ short isoform that resists the inhibition induced 
by PI3K inhibitors, such as idelalisib and wortmannin, and has been 
associated with more aggressive tumors [118]. 
In pancreatic ductal adenocarcinoma (PDAC), MNK-dependent 
phosphorylation of eIF4E correlates with disease grade, early onset of 
disease, and worse prognosis. Gemcitabine up-regulates SRSF1, which 
favors the AS of MNK2 to generate MNK2b. This SV lacks part of the 
exon 13 and hence losses the binding site required to interact with 
MAPK, which enhances eIF4E phosphorylation and hence reduces 
gemcitabine-induced apoptosis and promotes cancer cell survival 
[7,119]. Moreover, experimentally induced expression of SRPK1 confers 
resistance to treatment with gemcitabine [120]. In contrast, SRSF1 
silencing, using siRNA, abolishes MNK AS, reducing eIF4E phosphory-
lation and restoring the sensitivity of PDAC cells to gemcitabine [119]. 
In this sense, gemcitabine resistant-PDAC cells exhibited a switch in 
the AS of pyruvate kinase gene (PKM). This gene encodes two SVs, PKM1 
and PKM2, through the incorporation of mutually exclusive exons. The 
latter is involved in tumor development. Moreover, PTBP1 is also up- 
regulated in pharmacoresistant PDAC cells, which promotes PKM2 
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pre-mRNA, favoring the expression of PKM1 and restoring the sensi-
tivity to gemcitabine [121]. Interestingly, miR-374b down-regulation 
has been shown to affect PKM1/PKM2 splicing by modifying hnRNPA1 
expression in sorafenib resistant HCC cells [122]. 
Three novel, truncated FGFR1 variants (FGFR1v) have been identi-
fied in salivary adenoid cystic carcinoma (SACC) [123]. They are 
generated by premature termination codon by inclusion in the mature 
mRNA of intronic segments. These SVs are cell surface proteins lacking 
their intracellular domain, whose expression enhances pAKT activity, 
rendering SACC cells more resistant to FGFR1 inhibitors, such as dovi-
tinib [7,123]. 
9. Role of AS in MPR-6. Changes affecting the tumor 
microenvironment 
The surrounding microenvironment may also affect tumor cells 
altering their response to pharmacotherapy (MPR-6) (Fig. 1, Table 2). 
Splicing events have been detected both in the secretome [124] and in 
extracellular vesicles (EVs) derived from cancer cells [125], which may 
have an impact on the drug resistance of other cancer cells located in 
their vicinity. For example, EVs released by apoptosis-resistant AML 
cells contain an enriched amount of SF3B3 and hnRNPA3, which can be 
taken up by apoptosis-sensitive AML cells altering their drug resistance 
[126]. Another example is observed in glioblastoma (GB) cells, where 
apoptotic cells release EVs containing the splicing factor RBM11. This is 
a tissue-specific splicing regulator selectively expressed in the brain, 
cerebellum, and testis, and to a lower extent in the kidney [127]. Upon 
uptake of these EVs by non-apoptotic GB cells, RBM11 can alter the 
splicing profile of MDM4 and Cyclin D1 toward the expression of more 
oncogenic isoforms, thereby promoting their proliferation and drug 
resistance [125]. Tunneling nanotubes can mediate the transport of 
vesicles between bone marrow stromal cells and CML cells. The cargo of 
these vesicles, which is enriched in splicing factors, transfers the ability 
to protect CML cells from imatinib-induced apoptosis [128]. 
Angiogenesis is a key determinant of the tumor microenvironment. 
The use of an alternative 3′ SS for exon 8 definition in VEGFA pre-mRNA 
generates the SV VEGFA145b, which acts as a reservoir of angiogenic 
growth factors in the tumor stroma leading to bevacizumab resistance in 
colorectar adenocarcinoma [129]. 
10. Role of AS in MPR-7. Changes affecting phenotypic 
transition 
In the group of MPR-7 changes favoring malignant phenotypic 
transitions such as EMT and the appearance of cancer stem cells (CSC)- 
like traits, have been included (Fig. 1, Table 2). EZH2, the catalytic 
subunit of the epigenetic modulator PRC2, promotes cancer develop-
ment and progression through epigenetic silencing of tumor suppressors 
by trimethylation of histone H3. Exon 14 inclusion during splicing, 
which is promoted by SF3B3, results in an active SV accounting for stem- 
cell-like epigenetic state of prostate cancer cells that is accompanied by 
enzalutamide resistance [130] 
Alterations in the expression of different splicing regulatory proteins 
have been described as precursors of EMT, which determines an un-
satisfactory response to pharmacological treatment. In turn, during 
EMT, the expression of several components of the splicing machinery is 
markedly changed [131,132]. Thus, epithelial splicing regulatory pro-
teins 1 (ESRP1) and 2 (ESRP2), are epithelial cell-specific regulators of 
AS. Both splicing factors are down-regulated during EMT. In breast 
cancer, the balance between ESRP1 and hnRNPM is critical for stimu-
lating EMT and chemoresistance. Whereas hnRNPM favors mesen-
chymal phenotype due to its effect enhancing exon skipping and TGFβ 
signaling, ESRP1 favors epithelial phenotype by enhancing exon reading 
[133]. Both proteins act as competitive factors binding to cis-elements in 
target pre-mRNAs to antagonize theirs AS [134]. 
The CD44 gene, which is involved in EMT, has 10 constant exons and 
10 variable exons (v1-v10) located in the pre-mRNA between constant 
exon 5 and 16. Thus, several SVs can be generated during AS by inclu-
sion, which is promoted by ESRP1, or exclusion, favored by hnRNPs, of 
variable exons. CD44v6 and CD44v9 interact with CD95, the death re-
ceptor, interfering with death receptor signaling and inhibiting 
apoptosis, which results in chemoresistance [133,135]. Moreover, the 
expression of the variant containing exons v8-10 (CD44v8-10) has been 
associated with enhanced chemoresistance in gastrointestinal, breast, 
ovarian, and prostate cancer cells [136,137]. The up-regulation of this 
SV has been found in cisplatin-resistant urothelial cancer cells [138] and 
has been associated with docetaxel resistance in prostate cancer. 
Accordingly, the detection of CD44v8-10 mRNA in serum exosomes has 
been proposed as a prognostic marker [132,139]. 
The expression of HNRNPAB is increased in many cancers, including 
HCC, which favors EMT in a SNAIL-dependent manner [140]. Aberrant 
splicing in other genes such as RON and RAC1B also promotes EMT 
(MPR-7) and angiogenesis (MPR-6), which hamper the effect of anti-
angiogenic drugs [141,142]. Moreover, the overexpression of the 
oncogenic SVs of the protein H-Ras in cancer cells results in the release 
of exosomes containing splicing factors such as SF3B1 and SRSF1, which 
are suggested to be taken up by distant cells where they promote EMT, 
leading to more tumor aggressiveness and poorer response to the 
treatment [143]. 
Three SVs of the transcription factor OCT4 have been described. In 
colon cancer cells, overexpression of the SV OCT4B1 promoted invasion 
and migration but also enhanced chemoresistance because OCT4B1 
suppressed the sensitivity to oxaliplatin by up-regulating ABCB1 and 
ABCG2 export pumps [144]. 
In HER2-positive breast cancer, the presence of phenotypic changes 
toward that of CSCs, which correlates with enhanced aggressiveness and 
pharmacoresistance, has been associated with the appearance of aber-
rant SVs. This MPR-7 markedly depends on SRSF3 and hnRNPH1 
expression. These changes are clinically relevant because the expression 
levels of these SVs (e.g., Δ16HER2, P100-HER2, and Herstatin) deter-
mine the response to trastuzumab [145]. 
11. Conclusions and Perspectives. 
The information analyzed here permits to reach several valuable 
conclusions. In the first place, similarly to its impact on interindividual 
variability in healthy people, the existence of splice events increases the 
diversity of tumor cell phenotypes favoring tumor heterogeneity 
regarding crucial malignant characteristics, such as pharmacoresist-
ance. Altered AS can result from changes in the expression and function 
of regulatory elements of the exon-recognition machinery in tumor cells, 
some of them affected by AS themselves, during carcinogenesis, pro-
gression, and response to treatment. 
Considering the high frequency of aberrant splicing associated with 
cancer pathogenesis and therapy, pharmacological intervention to 
modulate AS may provide new therapeutic opportunities in cancer 
[146]. Several preclinical studies have investigated the usefulness of 
small molecules as modulators of splicing. An important drawback of 
this strategy is that the targets of most of these agents are constitutive 
components of the spliceosome, whose manipulation often results in 
adverse side effects. Nevertheless, certain selectivity for individual 
splice events has been identified, which opens a window of hope in this 
line of research [147]. This is important because cancer cells are 
markedly active regarding replication, which requires a high rate of pre- 
mRNA processing. Accordingly, it is reasonable to expect that cancer 
cells could be more sensitive than healthy quiescent cells to pharma-
cological manipulation of the splicing machinery using novel drugs. 
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